National Institutes of Health

SonoMotion Inc. develops non-invasive medical devices for kidney stone disease, including Break Wave for fragmenting large stones and Stone Clear to remove fragments within about 15 minutes in office settings without general anesthesia or X-ray radiation. The company, founded in 2012 and based in San Mateo, California, focuses on office-based procedures that aim to simplify treatment, reduce hospital visits, and offer cost-efficient care for kidney stone patients.

Neuronoff is a medical device company focused on developing the Injectrode, an injectable metal electrode delivered through a small needle to create neuromodulation interfaces inside the body across various targets. The platform aims to simplify complex neuromodulation surgeries into outpatient procedures and enables electrical stimulation of hard-to-reach anatomical targets using wired or wireless energy transfer to restore and improve organ activity.

IVOS Medical is an innovative medical device company focused on advancing airway management technology.

Rhealth is a biotechnology company that develops AI-powered health management solutions for hospitals, offering a platform that delivers comprehensive health information to clinicians and patients and integrates portable diagnostics and monitoring capabilities to support timely, data-driven care.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

BioCircuit Technologies, Inc. is a medical device company based in Atlanta, Georgia, founded in 2016. The company specializes in developing noninvasive electrophysiology devices that monitor, control, and repair peripheral nerves. By utilizing multi-electrode arrays and proprietary algorithms, BioCircuit's products enable clinicians to diagnose health conditions more effectively, track the progression of symptoms over time, and select tailored treatments for individual patients. This innovative approach enhances the ability of healthcare providers to address nerve-related health issues with greater precision and efficiency.

BMI OrganBank develops innovative medical devices and perfusion technology to enhance organ and tissue preservation for transplantation. The company collaborates with academic institutions to expand the possibilities of organ transplantation, aiming to improve patient outcomes.

ReShape Lifesciences is a medical device company focused on technologies to treat obesity and metabolic diseases. The company develops and commercializes products designed to provide less invasive options for weight loss, including the Lap-Band System, an adjustable gastric banding device for long-term obesity management. It also has the ReShape Vest system, an investigational laparoscopically implanted device that wraps around the stomach and is designed to support weight loss without permanent changes to the GI tract; the Vest is primarily marketed outside the United States. The company traces its origins to EnteroMedics and adopted the ReShape Lifesciences name in 2017. It is headquartered in San Clemente, California, and operates in multiple international markets.

Novel Microdevices, LLC is a medical device company that specializes in the development of handheld devices for molecular diagnostics. Founded in 2014 and headquartered in Annapolis, Maryland, the company has created the NOVEL DX device, which employs microfluidics technology to analyze raw biological samples at the point of care. This device delivers results in approximately 30 minutes, allowing healthcare professionals to achieve lab-quality diagnostics without the need for a traditional laboratory setting. Novel Microdevices caters to various sectors, including clinical diagnostics, biodefense, food safety, forensics, drug discovery, animal care, and agriculture, thus addressing a wide range of applications in health and safety.

Young Heart Valve is a Polymeric, Hyaluronan-Enhanced Transcatheter Aortic Valves which were developed by engineers with inspiration from nature. The future of heart valve intervention is being altered by Young Heart Valve. Animal tissue is no longer required thanks to Young Heart Valve. Hyaluronan is included into the leaflets of Young Heart Valve's RejuvenateTM TAVR device, forming a biomolecular interpenetrated network that has been shown to be resistant to calcification and thrombosis.

CareTaker Medical develops wireless patient monitoring devices. Its flagship product, CareTaker, is a wearable system that measures continuous beat-by-beat blood pressure, heart rate, respiration rate, and other hemodynamic parameters using only a finger cuff. The device securely transmits data over cellular networks or Bluetooth to enable remote patient monitoring within hospitals and during transport.

Teal Health specializes in developing at-home cervical cancer screening devices, aiming to enhance convenience, privacy, and accessibility for women. Their FDA-approved platform includes a sampling device, virtual consultations with licensed providers, secure laboratory testing, an online results portal, and coordination of follow-up care.

CardieX is a global health technology company focused on cardiovascular health management, including hypertension and vascular disorders. It designs, manufactures, and markets medical devices and digital health tools that measure cardiovascular risk, monitor arterial stiffness and central blood pressure, and support patient management across hospitals, clinics, research institutions, and pharmaceutical companies in the Americas, Europe, and the Asia-Pacific region. The company offers TeleHealth services with digital, e-commerce, and mobile tools enabling online connections with health coaches. Its products include devices based on patented arterial stiffness and central blood pressure technologies, and wearables with health analytics. CardieX collaborates with external partners to develop wearable sensors and hypertension programs. The company traces its origins to AtCor Medical and rebranded to CardieX in 2018. CardieX was founded in 1994 and is headquartered in Sydney, Australia.

Resvita Bio develops and manufactures engineered probiotics for treating skin-related diseases, including cancer. Leveraging a synthetic biology platform, the company uses genetically engineered bacteria to produce and deliver therapeutic proteins directly to affected skin areas, providing continuous treatment and addressing limitations of traditional therapies. It targets conditions such as Netherton Syndrome and Severe Atopic Dermatitis, pursuing novel methods to manage skin disorders through localized, sustained protein delivery.

Lasarrus is a medical device company founded in 2013 and headquartered in Baltimore, Maryland. The company specializes in developing wearable devices aimed at enhancing the physical therapy experience for patients, particularly those with chronic obstructive pulmonary disease. Lasarrus's innovative device facilitates remote monitoring and telemedicine by capturing physiological and range-of-motion data from various points on the body. This technology provides patients with an affordable, comfortable, and non-invasive means to track their health routines and accelerate their recovery process.

Subtle Medical is a healthcare technology company that develops artificial‑intelligence software for magnetic resonance and positron emission tomography imaging. Its flagship products, SubtleMR and SubtlePET, are FDA‑cleared and CE‑marked tools that enhance image quality by reducing noise and sharpening detail, allowing scans to be performed faster and with lower radiation or contrast dose. The company’s deep‑learning algorithms integrate with any scanner without changing existing workflows, enabling imaging centers and hospitals to increase throughput and improve patient safety. Subtle Medical also offers a vendor‑agnostic AI platform that delivers analytics and support to clinical imaging providers. Founded in 2017 and headquartered in Menlo Park, California, the firm has received an NIH SBIR grant and an RSNA award for its GAD technology.

Penderia Technologies is a medical device company focused on innovative orthopedic solutions. It develops implantable, battery-less sensors for monitoring injury and healing progress in real-time, enabling personalized rehabilitation therapies.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Cortechs.ai is a developer of brain image analysis software that enhances clinical insight through quantitative imaging. The company's innovative solutions are utilized by neurologists and radiologists in numerous clinics and research centers globally. Its software provides a practical and cost-effective approach to quantifying brain structures, aiding medical professionals in the evaluation of various neurological conditions, including Alzheimer's disease, multiple sclerosis, epilepsy, and traumatic brain injury. Through its advanced imaging technology, Cortechs.ai aims to improve diagnostic accuracy and treatment outcomes in the field of neurology.

VenoStent develops bioabsorbable smart polymer wraps for vascular surgeries. Its flagship product, SelfWrap, is a perivascular wrap designed to reduce failures at the vein-artery junction in dialysis patients by promoting outward vein growth and providing custom-fit mechanical support. The company's technology acts as an external stent, reducing surgery time, infection risk, and wound reopening while improving vein usability and durability.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Annoviant is a healthcare company focused on the development of innovative medical devices, specifically tissue-based valve and conduit replacement systems. These devices are designed to address congenital deficiencies by replacing or patching structures that are either absent or underdeveloped. Annoviant's products are characterized by their regenerative capabilities, as well as their resistance to thrombosis, calcification, and infection. By maintaining essential mechanical properties, these devices empower clinicians to enhance clinical outcomes for substitute conduit arteries in infants and children, significantly reducing the likelihood of repeat surgeries.

Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Amydis is a privately-held pharmaceutical company dedicated to developing innovative diagnostic tools for detecting diseases linked to amyloid protein deposits. Its core technology involves novel compounds that fluoresce upon binding to amyloid proteins, enabling non-invasive diagnosis. Amydis' primary focus is on early-stage Alzheimer's disease detection, with other potential applications including Parkinson's disease, Creutzfeldt-Jakob disease, and various forms of amyloidosis. The company aims to provide faster, more accessible, and affordable diagnostic solutions compared to existing methods, contributing to better healthcare decisions for patients and their families.

Virtuoso Surgical develops endoscopic robotic tools for minimally invasive surgery. Its Virtuoso robotic surgery system enables surgeons to overcome limitations of traditional endoscopes, with needle-sized robotic arms that reach difficult-to-access areas. The company focuses on simplifying endoscopic procedures and provides a range of tools to help surgeons perform operations more effectively and potentially improve patient outcomes.

On average, we spend a third of our lives in bed. Our self-positioning bed; the Korus™, combined with our AI-driven software, is designed to provide precise sleep therapies improving lifestyle and medical care that benefits sleep wellness and faster recovery at home.

Endomimetics develops bio-nanometric coating technology for stents, aiming to enhance care for patients with kidney disease. Its innovative coating mimics human tissue, reducing complications and surgeries associated with implanted devices.

Rivanna Medical, LLC is a medical technology company founded in 2010 and headquartered in Charlottesville, Virginia. The company specializes in the development and commercialization of Accuro, an advanced ultrasound-based system designed to enhance the application of spinal and epidural anesthesia through automated three-dimensional navigation of the lumbar spine. In addition to its primary focus on anesthesia, Rivanna Medical's technology also encompasses various imaging applications, including diagnostic imaging for musculoskeletal and abdominal anatomies. By leveraging innovative ultrasound technology, Rivanna Medical aims to lower healthcare costs, improve patient outcomes, and minimize the risks associated with radiation from traditional X-ray-based imaging.

RevBio is a biotechnology company focused on developing innovative solutions for bone repair. Its flagship product, Tetranite, is an injectable, self-setting, osteoconductive bone adhesive biomaterial designed to bond bone to bone and bone to metal in challenging environments. Tetranite is currently undergoing FDA review for various applications, including oral, craniofacial, orthopedic, and neurosurgical uses. This synthetic adhesive biodegrades over time, being replaced by new bone as part of the natural bone remodeling process, thus serving as a scaffold to promote bone growth. By utilizing this unique material, RevBio aims to reduce the duration and complexity of medical procedures, facilitate more minimally invasive surgeries, and enhance patient outcomes by decreasing pain, recovery time, and overall healthcare costs. The company is actively developing a portfolio of applications tailored for both dental and orthopedic fields.

BioCircuit Technologies, Inc. is a medical device company based in Atlanta, Georgia, founded in 2016. The company specializes in developing noninvasive electrophysiology devices that monitor, control, and repair peripheral nerves. By utilizing multi-electrode arrays and proprietary algorithms, BioCircuit's products enable clinicians to diagnose health conditions more effectively, track the progression of symptoms over time, and select tailored treatments for individual patients. This innovative approach enhances the ability of healthcare providers to address nerve-related health issues with greater precision and efficiency.

Rhaeos is a pioneering company that has developed the world's first wearable shunt monitor, designed to enhance the quality of care for patients with hydrocephalus. Utilizing a novel thermal biosensor, Rhaeos addresses a critical clinical need by offering noninvasive, wireless patches that detect fluid flow in various bodily systems, including blood, lymph, and cerebrospinal fluid. This innovative technology enables timely treatment for chronic medical conditions, particularly in the field of neurosurgery. Founded through collaborative efforts at Northwestern University, Rhaeos exemplifies a multidisciplinary approach, integrating expertise from engineering, medicine, and management to advance patient care.

SpineX develops and tests neuromodulation technologies for non-invasive devices that aid recovery in individuals with neurological conditions such as strokes, spinal cord injuries, multiple sclerosis, and cerebral palsy. Their focus is on restoring bladder, bowel, respiration, sexual, and sensorimotor functions.

Golden Helix is a developer of bioinformatics solutions specializing in genomic data analysis, with a focus on supporting life science research and translational medicine. With over 20 years of experience, the company provides innovative cloud-based software that empowers scientists and healthcare professionals to manage, analyze, and visualize complex genomic and phenotypic data. By streamlining the annotation and filtering of variants from next-generation sequencing, Golden Helix enables biologists and researchers of varying expertise to conduct intricate analyses and produce meaningful insights from large genomic datasets without the constant need for specialized bioinformatics support.

ReShape Lifesciences is a medical device company focused on technologies to treat obesity and metabolic diseases. The company develops and commercializes products designed to provide less invasive options for weight loss, including the Lap-Band System, an adjustable gastric banding device for long-term obesity management. It also has the ReShape Vest system, an investigational laparoscopically implanted device that wraps around the stomach and is designed to support weight loss without permanent changes to the GI tract; the Vest is primarily marketed outside the United States. The company traces its origins to EnteroMedics and adopted the ReShape Lifesciences name in 2017. It is headquartered in San Clemente, California, and operates in multiple international markets.

Subtle Medical is a healthcare technology company that develops artificial‑intelligence software for magnetic resonance and positron emission tomography imaging. Its flagship products, SubtleMR and SubtlePET, are FDA‑cleared and CE‑marked tools that enhance image quality by reducing noise and sharpening detail, allowing scans to be performed faster and with lower radiation or contrast dose. The company’s deep‑learning algorithms integrate with any scanner without changing existing workflows, enabling imaging centers and hospitals to increase throughput and improve patient safety. Subtle Medical also offers a vendor‑agnostic AI platform that delivers analytics and support to clinical imaging providers. Founded in 2017 and headquartered in Menlo Park, California, the firm has received an NIH SBIR grant and an RSNA award for its GAD technology.

Daxor Corporation is a medical device and biotechnology company based in New York, founded in 1970. It specializes in blood volume measurement, offering the BVA-100 Blood Volume Analyzer, the first FDA-approved instrument for the rapid and direct measurement of a patient's true blood volume. This device is utilized in diagnosing and managing various medical conditions, including congestive heart failure, critical care medicine, hypertension, and anemia. In addition to its core product, Daxor provides cryobanking services such as semen banking and blood storage, along with andrology and general laboratory testing services. The company also collaborates with the Uniformed Services University of the Health Sciences to research the effectiveness of its diagnostic tests in traumatic injury contexts. Daxor was previously known as Idant Corporation before rebranding in May 1973.

NeuroGeneces develops an artificial intelligence driven brain health assessment platform to detect early signs of neurodegeneration before cognitive symptoms appear. Its Brain Age test analyzes patient EEG data collected via a sleep headband and ML software, benchmarking against a proprietary normative database to provide objective measures of brain function. The platform enables healthcare practitioners to identify at-risk individuals and guide preventive interventions through early behavioral strategies, offering more comprehensive insights than traditional biomarkers.

Founded in 2006, Civatech Oncology is a medical device company based in Durham, North Carolina. It specializes in developing polymer-based devices for localized low-dose-rate radiation cancer treatment. The company's patented technology enables customizable devices tailored to specific tumor types, with its first product, the CivaString, FDA-cleared for treating solid tumors.

DiagMetrics is a company that specializes in mask-based diagnostic systems designed to detect respiratory diseases, including Covid-19. Their innovative technology allows for the retrofitting of existing masks to convert breath vapor into a fluid biosample, facilitating non-invasive testing. The system is equipped with Bluetooth capabilities, enabling users to receive test results directly on their smartphones. By providing accessible and efficient diagnostic solutions, DiagMetrics aims to democratize testing and enhance the early detection of respiratory illnesses.

Novel Microdevices, LLC is a medical device company that specializes in the development of handheld devices for molecular diagnostics. Founded in 2014 and headquartered in Annapolis, Maryland, the company has created the NOVEL DX device, which employs microfluidics technology to analyze raw biological samples at the point of care. This device delivers results in approximately 30 minutes, allowing healthcare professionals to achieve lab-quality diagnostics without the need for a traditional laboratory setting. Novel Microdevices caters to various sectors, including clinical diagnostics, biodefense, food safety, forensics, drug discovery, animal care, and agriculture, thus addressing a wide range of applications in health and safety.

EndoTheia is a medical device company that develops flexible endoscopy technology, including a system that uses micro-machined smart materials to create dexterous manipulators at millimeter and sub-millimeter scales. The solution aims to improve therapeutic outcomes in complex flexible endoscopic procedures by enabling more precise and capable manipulation within confined anatomical spaces.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Co-Diagnostics, Inc. is a molecular diagnostics company based in Salt Lake City, Utah, founded in 2013. The company specializes in the development, manufacture, and marketing of advanced diagnostic technologies that focus on the detection and analysis of nucleic acid molecules, such as DNA and RNA. In addition to creating reagents for diagnostic tests, Co-Diagnostics offers self-contained lab systems that incorporate diagnostic equipment from other manufacturers. The company also leverages its proprietary technology to design targeted tests for identifying genetic markers, which can be utilized in various industries beyond infectious diseases, while licensing these tests to specific customers.

Founded in 2021, Domus Diagnostics specializes in respiratory disease home testing services via its care diagnostics platform. The company offers affordable, user-friendly, and accurate testing kits designed to address infectious disease outbreaks promptly.

Sensor-Kinesis Corporation develops innovative medical devices focused on pathogen and virus detection. Founded in 2013 and based in Los Angeles, the company is advancing proprietary biosensor technology that integrates flexible micro biosensor chips with computer systems. These chips are designed to detect specific biomolecules and can be printed on various surfaces, enabling widespread application across multiple industries, including healthcare, food safety, and pharmaceuticals. By linking these sensors to smart devices, users can transmit and analyze biological signals in real time, facilitating improved health monitoring. Sensor-Kinesis aims to empower healthcare professionals and individuals with affordable, portable devices that provide enhanced detection capabilities for diseases and health-related risks, promoting better health outcomes and safety.

Founded in 1998, Second Sight is a medical device company dedicated to developing implantable visual prosthetics. Their primary product, the Argus II Retinal Prosthesis System, is designed to provide artificial vision to individuals blinded by outer retinal degenerations such as Retinitis Pigmentosa.

CardieX is a global health technology company focused on cardiovascular health management, including hypertension and vascular disorders. It designs, manufactures, and markets medical devices and digital health tools that measure cardiovascular risk, monitor arterial stiffness and central blood pressure, and support patient management across hospitals, clinics, research institutions, and pharmaceutical companies in the Americas, Europe, and the Asia-Pacific region. The company offers TeleHealth services with digital, e-commerce, and mobile tools enabling online connections with health coaches. Its products include devices based on patented arterial stiffness and central blood pressure technologies, and wearables with health analytics. CardieX collaborates with external partners to develop wearable sensors and hypertension programs. The company traces its origins to AtCor Medical and rebranded to CardieX in 2018. CardieX was founded in 1994 and is headquartered in Sydney, Australia.

Prapela is a pediatric medical device company focused on enhancing the health of newborns through noninvasive stimulation therapy. Its primary product, a reusable pad designed for placement in hospital bassinets or incubators, provides gentle stimulation that aids in regulating breathing control and improving oxygenation. By addressing common clinical issues such as irregular breathing and low oxygen levels, Prapela aims to improve cardiorespiratory outcomes for infants while reducing the need for pharmacotherapy and minimizing the duration of conventional treatments. Since its inception, Prapela has gained recognition as a leading innovator in the pediatric medical device sector, collaborating with neonatologists, the National Institutes of Health, and the FDA to advance its mission of improving newborn health.

Actuated Medical, Inc. is a medical device company based in Bellefonte, Pennsylvania, that focuses on designing, developing, and manufacturing innovative solutions for healthcare. Established in 2006, the company specializes in devices that facilitate occlusion clearing, tissue penetration, and MRI-guided surgical procedures. Their product line includes systems like TubeClear and NG-Clear, which are designed to clear clogs in feeding tubes, as well as devices for controlled tissue penetration, such as the GentleSharp Device and OsteoAccess System. Additionally, Actuated Medical offers MRI-compatible technologies, including direct drive piezoelectric ultrasonic motors that enhance diagnostic and surgical capabilities during imaging procedures. The company's commitment to improving patient care is reflected in their range of minimally invasive instruments and transdermal delivery systems. Actuated Medical was previously known as Piezo Resonance Innovations, Inc. before rebranding in September 2011.

PharmaJet develops and markets needle-free jet injectors for vaccine delivery, enabling administration without a needle and reducing sharps injuries, needle reuse, cross-contamination, and medical waste. Its Stratis and Tropis platforms are designed to deliver vaccines intramuscular, subcutaneous, or intradermal across various volumes, offering a potential return on investment by lowering risk and waste. Founded in 2005 and based in Golden, Colorado, PharmaJet focuses on delivering safe, user-friendly devices that support immunization programs and aim to simplify injections while expanding access to vaccination.

Linshom develops continuous respiratory monitoring solutions for bedside and home use, providing an operating-room quality respiratory profile including tidal volume through wearable, FDA-cleared sensors. The system enables continuous predictive monitoring of respiration, delivering early warnings of respiratory decline to help reduce rapid-response activations, rescue events, and ICU transfers. By capturing respiration data and relative tidal volume at the point of care, Linshom addresses an unmet clinical need with actionable insights for clinicians.

BIOS Health is a pioneering company focused on developing neural digital therapies by harnessing data-driven insights from the human nervous system. Co-founded by researchers from Cambridge University, the firm aims to revolutionize precision medicine through the identification of neural biomarkers that link nerve activity to various medical conditions. BIOS's innovative approach holds promise for treating chronic diseases such as hypertension, diabetes, rheumatoid arthritis, and neurodegenerative disorders like Parkinson's and Alzheimer's. The company's expertise encompasses a diverse range of fields, including neuroscience, machine learning, software engineering, and biotechnology, allowing it to create advanced solutions for improving the quality of life for individuals suffering from these conditions. Additionally, BIOS is engaged in developing prosthetic connectors that standardize the interface between bionic devices and the body's nervous and soft-tissue systems, enabling enhanced control and feedback for patients with prosthetics.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Neurovations, a patient care and innovation company, was founded in 1992 by CEO Dr. Eric Grigsby. Today, Neurovations is a national leader in medical device and pharmaceutical innovation, clinical research, and a world-class education program focusing in pain and neuroscience. Dr. Grigsby is deeply connected to the healthcare community through our non-profit HealthRoots Foundation. Our unwavering mission is to inspire hope and to contribute to the health and well-being of our patients and communities through integrated clinical practice, research, and education.

Rescue Biomedical Services is a medical equipment repair company serving Southern California.

Efemoral Medical is a medical technology company focused on durable, minimally invasive therapies for peripheral vascular disease. The company is developing a bioresorbable intravascular stent designed to maintain or restore patency in peripheral vessels, supporting effective treatment and improved quality of life for patients with PAD. Its initial offering, the Efemoral Vascular Scaffold System with FlexStep Technology, embodies a multi-element approach to endovascular intervention for peripheral arteries.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Evaxion Biotech is a clinical-stage company leveraging AI-immunology™ technology to decode the human immune system, developing novel immunotherapies for cancer and infectious diseases. Its pipeline includes three patient-specific cancer therapies in Phase I/IIa trials and vaccines targeting bacterial and viral infections.

Matregenix is a MedTech company founded in 2018 by Sherif Soliman and based in Irvine, California. The company specializes in the development and manufacturing of advanced nanofibrous materials for various medical applications. Its flagship product, MatriNova, is a barrier membrane designed specifically for periodontal surgeries, featuring customizable properties such as predictable resorption time and ease of handling. Matregenix employs electrospinning technology to create innovative membrane solutions that cater to the filtration and biomedical sectors. In addition to its product offerings, the company provides comprehensive contract development and manufacturing services, assisting manufacturers in bringing their medical products to market effectively.

Founded in 2019, Sequitur Health specializes in developing innovative medical devices aimed at saving and enhancing lives. Based in Scottsdale, Arizona.

Cortechs.ai is a developer of brain image analysis software that enhances clinical insight through quantitative imaging. The company's innovative solutions are utilized by neurologists and radiologists in numerous clinics and research centers globally. Its software provides a practical and cost-effective approach to quantifying brain structures, aiding medical professionals in the evaluation of various neurological conditions, including Alzheimer's disease, multiple sclerosis, epilepsy, and traumatic brain injury. Through its advanced imaging technology, Cortechs.ai aims to improve diagnostic accuracy and treatment outcomes in the field of neurology.

Virtuoso Surgical develops endoscopic robotic tools for minimally invasive surgery. Its Virtuoso robotic surgery system enables surgeons to overcome limitations of traditional endoscopes, with needle-sized robotic arms that reach difficult-to-access areas. The company focuses on simplifying endoscopic procedures and provides a range of tools to help surgeons perform operations more effectively and potentially improve patient outcomes.

Founded in 2018, PETcoil is a medical technology company dedicated to improving healthcare through innovative imaging solutions. With roots tracing back to Stanford University, their core technology enables simultaneous PET and MRI imaging using a radiofrequency-penetrable PET insert system. Their mission is to create affordable, high-performance molecular imaging systems that empower doctors for early and accurate disease diagnosis.

Founded in 1998, Second Sight is a medical device company dedicated to developing implantable visual prosthetics. Their primary product, the Argus II Retinal Prosthesis System, is designed to provide artificial vision to individuals blinded by outer retinal degenerations such as Retinitis Pigmentosa.

Aural Analytics, Inc. is a Scottsdale, Arizona-based company founded in 2015 that specializes in brain health monitoring through innovative technology. The company has developed a multi-modal analytics platform that utilizes artificial intelligence, signal processing, and speech analytics to detect subtle changes in neurological health. By converting smartphones and tablets into effective brain health monitors, Aural Analytics enables the collection of objective and interpretable data. This technology supplements traditional functional rating scales used in clinical trials, providing continuous and reliable metrics for assessing the effectiveness of medical interventions. Aural Analytics' platform captures clinically relevant speech, fine motor, and linguistic samples to offer healthcare professionals accurate assessments of patient health, thereby enhancing the understanding of disease progression.

Eliaz Therapeutics is focused on developing innovative medical devices aimed at treating life-threatening diseases that are currently difficult to manage. The company's flagship device utilizes a patented apheresis column designed to selectively remove galectin-3 from human blood. This device targets both bound and free galectin-3, a protein linked to various serious health conditions, including diabetes, chronic kidney disease, organ fibrosis, and cancer. By efficiently eliminating galectin-3 from the bloodstream, the device offers a less invasive treatment option with fewer side effects compared to traditional therapies. Its design leverages a proprietary capturing molecule and is compatible with existing hospital systems, facilitating its adoption in clinical settings.

Ramona designs and manufactures a high-throughput microscopy toolset that enables cellular-level research across a wide field of view with synchronous data capture. The system relies on custom-designed control electronics and a large array of micro-cameras to deliver and process tens of gigapixels of object-specific data with high throughput, allowing users to capture, analyze, and securely store large-scale image data for faster, more informed decisions.

Founded in 2013, Immunicom specializes in developing innovative, non-pharmaceutical immunotherapy treatments for cancer, inflammatory diseases, and autoimmune disorders. The company's core product is a therapeutic device designed to filter blood and directly target various types of cancer, potentially enhancing the effects of other treatments with fewer side effects.

Bright Uro is an early-stage medical technology company developing a wireless, catheter-free urodynamic monitoring system. This innovative device aims to improve the diagnosis and management of lower urinary tract symptoms by enabling spontaneous voiding in natural settings, providing more accurate and comfortable diagnostic assessments.

Modality.AI, Inc. is a healthcare technology company based in San Francisco, California, founded in 2018. It specializes in AI-powered solutions that enhance the efficiency of clinical trials for neurological and mental health therapies. The company's platform utilizes conversational AI to engage patients through naturalistic spoken interaction, allowing for continuous health assessments anytime and anywhere. By analyzing multimodal data, including audio-visual biomarkers, Modality.AI provides objective measures that correlate with clinical outcomes. This innovative approach enables pharmaceutical companies to conduct self-driven assessments and improve the monitoring of health conditions, ultimately facilitating more effective clinical trials.

Sonavex develops imaging technologies for vascular and surgical care, employing ultrasound to detect postoperative blood clots at the point of care and to measure intravascular flow metrics for timely decision making. It also develops bioresorbable, echogenic devices to mark at-risk vessels and to collect data on arteriovenous fistula flow, diameter, and depth at dialysis clinics to assess maturation and anticipate future complications. Based in Baltimore, Maryland, Sonavex focuses on delivering data-driven visualization of vessel health to improve surgical and dialysis patient outcomes.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Enspectra Health, based in Mountain View, California, develops advanced imaging systems for medical research and diagnosis. Founded in 2012, the company has pioneered the world's first handheld multiphoton imager for human use, capable of visualizing beneath the skin in real-time. Its innovative system combines reflectance confocal and multiphoton laser scanning microscopy to generate multispectral images, enhancing dermatologists' ability to diagnose and treat skin conditions, particularly cancers. Enspectra Health delivers these imaging systems to researchers studying various tissues and has a track record of delivering such systems since its inception.

Genomenon, Inc. is a software development company based in Ann Arbor, Michigan, that specializes in tools for genetic diagnosis and discovery. Founded in 2014, it provides a suite of diagnostic and discovery solutions that enable physicians, researchers, and pharmaceutical companies to rapidly and accurately identify disease-causing variants from genomic sequencing data. The company’s flagship product, GENOMENON, automates the analysis of next-generation sequencing data, thereby enhancing decision-making processes in clinical settings and accelerating discoveries in genomics. With its focus on improving cancer diagnosis and treatment, Genomenon aims to support better patient outcomes through its innovative software solutions.

Epicore Biosystems, Inc. is a Cambridge, Massachusetts-based company that develops and commercializes a proprietary wearable microfluidic sensing platform designed for athletes. Founded in 2017, the company focuses on analyzing small droplets of sweat directly from the skin to measure a range of health and performance metrics. Its technology allows for non-invasive monitoring of sweat biomarkers, skin health, and physiological states in real-time, facilitating personalized management of hydration, nutrition, and overall health. Epicore's innovative platform is grounded in extensive research in microfluidics and soft materials, aiming to enhance athletic performance and health management through accessible and cost-effective solutions.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Subtle Medical is a healthcare technology company that develops artificial‑intelligence software for magnetic resonance and positron emission tomography imaging. Its flagship products, SubtleMR and SubtlePET, are FDA‑cleared and CE‑marked tools that enhance image quality by reducing noise and sharpening detail, allowing scans to be performed faster and with lower radiation or contrast dose. The company’s deep‑learning algorithms integrate with any scanner without changing existing workflows, enabling imaging centers and hospitals to increase throughput and improve patient safety. Subtle Medical also offers a vendor‑agnostic AI platform that delivers analytics and support to clinical imaging providers. Founded in 2017 and headquartered in Menlo Park, California, the firm has received an NIH SBIR grant and an RSNA award for its GAD technology.

Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.

Bleep provides best new CPAP solution on the market. Not sleeping sucks. Not sleeping and spending a fortune on CPAP devices that leak, fall off or leave marks on your face sucks even worse. That’s why they invented the DreamPort Sleep Solution – the world’s first-ever mask less CPAP device. The result is the smallest, lightest, most ergonomically accommodating CPAP solution on the market – a device that fits comfortably and doesn’t restrict your movement – enabling patients to get a better night’s sleep. Their goal is simple – to make the best bleeping CPAP products on the planet. They won’t stop until every sleep apnea patient is sleeping like a baby.

Medentum Innovations promotes health equity and transforming healthcare through affordable, high-performance point-of-care devices and AI diagnostics.

Delpor is a San Francisco-based developer of drug delivery technologies focused on creating sustained and pattern-specific release of proteins, peptides, and small molecules through small, non-mechanical subcutaneous implants. Its platforms include Prozor, a non-mechanical implantable device for delivering antipsychotics and other small molecules; NANOPOR, a membrane architecture-based implant offering prolonged release; and Delos PUMP, a self-contained implant that delivers drugs in programmed or pulse patterns, with potential for external activation to provide episodic dosing of therapies such as pain medications, antidotes, stimulants, or resuscitation agents. Founded in 2009, the company aims to improve medication adherence, safety, and efficacy by enabling convenient in-office implantation and simple administration, reducing the need for frequent injections. Delpor seeks to partner or license its technologies to advance long-acting formulations and pattern-specific dosing across therapeutic areas.

Anavasi Diagnostics is a medical technology company specializing in molecular diagnostic testing. The company has developed a clinical diagnostic platform aimed at providing rapid diagnosis of COVID-19. This platform enables the molecular analysis of patient samples in point-of-care settings, utilizing proprietary test kits specifically designed for COVID-19. By offering a rapid and affordable diagnostic solution, Anavasi Diagnostics equips medical personnel with the tools necessary for early detection and diagnosis of the virus, thereby enhancing patient care and response during health crises.

Lightengale is a medical device company focused on enhancing patient safety in healthcare settings, particularly in intensive care units. The company develops innovative devices that utilize light-emitting cables to illuminate individual intravenous (IV) lines from the pump to the patient. This technology addresses the critical issue of line mix-ups, which can lead to medication delivery errors. By facilitating clearer visualization of IV lines, Lightengale's devices empower nurses to trace and manage infusions more effectively, ultimately allowing them to dedicate more time to patient care. The company’s commitment to improving clinical outcomes underscores its role in advancing medical practices within the healthcare industry.

Annoviant is a healthcare company focused on the development of innovative medical devices, specifically tissue-based valve and conduit replacement systems. These devices are designed to address congenital deficiencies by replacing or patching structures that are either absent or underdeveloped. Annoviant's products are characterized by their regenerative capabilities, as well as their resistance to thrombosis, calcification, and infection. By maintaining essential mechanical properties, these devices empower clinicians to enhance clinical outcomes for substitute conduit arteries in infants and children, significantly reducing the likelihood of repeat surgeries.

Autonomous Healthcare is a medical technology company focused on transforming clinical care workflows through automation. It develops innovative technologies aimed at revolutionizing critical care and peri-operative care sectors. By continuously analyzing bedside monitoring data, the company introduces automated solutions that promptly address adverse events detected during patient monitoring. This proactive approach enables healthcare professionals to enhance patient outcomes and significantly reduce hospital lengths of stay, demonstrating a commitment to improving the efficiency and effectiveness of healthcare delivery.

Nanoscope Therapeutics Inc. is a biotechnology company based in Bedford, Texas, focused on developing innovative gene therapies aimed at restoring vision for individuals affected by retinal degenerative diseases, such as retinitis pigmentosa and dry age-related macular degeneration. Established in 2017, the company specializes in light-sensitive molecules and employs light-assisted gene delivery techniques to enable targeted treatment that re-sensitizes the retina, allowing patients to perceive low light levels. By utilizing a unique optogenetic approach, Nanoscope Therapeutics aims to deliver a solution for vision loss in patients where no effective cure currently exists, thereby advancing the potential for vision restoration in millions of affected individuals.

ThermoGenesis Holdings develops and markets automated technologies for chimeric antigen receptor (CAR)-T and other cell-based therapies. The company offers a range of solutions for clinical biobanking, point-of-care applications, and automation in immuno-oncology. Key products include the AXP Automated Cell Separation System for isolating stem cells from umbilical cord blood, the BioArchive Automated Cryopreservation System for cryogenic storage, the PXP Point-of-Care System for processing autologous stem cells at surgical centers or clinics, and the CAR-TXpress platform for streamlining CAR-T immunotherapy manufacturing. Additionally, ThermoGenesis provides X-Series products for various cell purification tasks and the AR-TXpress Platform for large-scale cellular processing. Founded in 1986 and headquartered in Rancho Cordova, California, the company was formerly known as Cesca Therapeutics Inc.

Vibrato Medical is focused on developing a noninvasive therapeutic ultrasound device aimed at treating Critical Limb Ischemia and Peripheral Arterial Disease. The company’s innovative approach is grounded in extensive research and recent advancements in ultrasound technology. Its device is designed to stimulate vasodilation and promote the growth of blood vessels, addressing symptoms and potentially preventing limb loss without the need for surgical intervention. This wearable technology allows patients to benefit from treatment in the comfort of their own homes, making it a convenient and accessible solution for those affected by these serious vascular conditions.

On average, we spend a third of our lives in bed. Our self-positioning bed; the Korus™, combined with our AI-driven software, is designed to provide precise sleep therapies improving lifestyle and medical care that benefits sleep wellness and faster recovery at home.

Amydis is a privately-held pharmaceutical company dedicated to developing innovative diagnostic tools for detecting diseases linked to amyloid protein deposits. Its core technology involves novel compounds that fluoresce upon binding to amyloid proteins, enabling non-invasive diagnosis. Amydis' primary focus is on early-stage Alzheimer's disease detection, with other potential applications including Parkinson's disease, Creutzfeldt-Jakob disease, and various forms of amyloidosis. The company aims to provide faster, more accessible, and affordable diagnostic solutions compared to existing methods, contributing to better healthcare decisions for patients and their families.

Eclipse Regenesis is a development-stage medical device company focused on harnessing the body’s tissue regeneration capabilities to treat Short Bowel Syndrome. Its flagship Eclipse XL1 System uses distraction enterogenesis to mechanically stimulate the growth of new, functional intestinal tissue, with the aim of restoring nutrient absorption in patients who lack sufficient small intestine. The company seeks to advance a restorative therapy through extensive research supported by SBS thought leaders worldwide, and the Eclipse XL1 System is currently investigational and not commercially available.

Hesperos, Inc. specializes in the development of Human-on-a-Chip microfluidic systems aimed at transforming toxicology testing and drug discovery efficacy evaluations. Founded by Michael L. Shuler and James J. Hickman, the company has pioneered advancements in creating individual organ-on-a-chip constructs and interconnected multi-organ systems. Hesperos's innovative pumpless platforms utilize serum-free cellular mediums to facilitate communication between multiple organ systems. The systems also incorporate integrated computational pharmacokinetics and pharmacodynamics modeling to assess live physiological responses through functional readouts from various tissues, including neurons, cardiac, muscle, and barrier tissues, as well as responses from the liver and pancreas. This technology enables clients to predict in vivo functions without relying on animal models, marking a significant step forward in biomedical research and development.

NeuroPace designs and markets implantable neuromodulation systems for neurological disorders, with a focus on epilepsy. Its flagship RNS System includes an implantable neurostimulator connected to depth and cortical leads that monitor brain activity and deliver targeted, responsive electrical stimulation to seizure onset regions. External components, including a programmer and software, enable device configuration and monitoring. Founded in 1997 and based in Mountain View, California, the company generates most revenue from selling RNS Systems to hospital facilities for implantation in patients with medically refractory partial epilepsy. NeuroPace aims to reduce or eliminate seizures through adaptive neuromodulation.

Ramona designs and manufactures a high-throughput microscopy toolset that enables cellular-level research across a wide field of view with synchronous data capture. The system relies on custom-designed control electronics and a large array of micro-cameras to deliver and process tens of gigapixels of object-specific data with high throughput, allowing users to capture, analyze, and securely store large-scale image data for faster, more informed decisions.

Enspectra Health, based in Mountain View, California, develops advanced imaging systems for medical research and diagnosis. Founded in 2012, the company has pioneered the world's first handheld multiphoton imager for human use, capable of visualizing beneath the skin in real-time. Its innovative system combines reflectance confocal and multiphoton laser scanning microscopy to generate multispectral images, enhancing dermatologists' ability to diagnose and treat skin conditions, particularly cancers. Enspectra Health delivers these imaging systems to researchers studying various tissues and has a track record of delivering such systems since its inception.

Prapela is a pediatric medical device company focused on enhancing the health of newborns through noninvasive stimulation therapy. Its primary product, a reusable pad designed for placement in hospital bassinets or incubators, provides gentle stimulation that aids in regulating breathing control and improving oxygenation. By addressing common clinical issues such as irregular breathing and low oxygen levels, Prapela aims to improve cardiorespiratory outcomes for infants while reducing the need for pharmacotherapy and minimizing the duration of conventional treatments. Since its inception, Prapela has gained recognition as a leading innovator in the pediatric medical device sector, collaborating with neonatologists, the National Institutes of Health, and the FDA to advance its mission of improving newborn health.

BiVACOR, Inc. is a Houston-based company founded in 2008 that specializes in designing and manufacturing advanced centrifugal heart pumps. The company develops an artificial heart-pumping device aimed at fully replacing the function of a failing heart. This innovative device features a compact, magnetically levitated rotor situated between opposing pump casings, utilizing rotary blood pump technology to deliver necessary cardiac output. By minimizing the risk of blood-cell damage and clotting, BiVACOR's technology offers patients a reliable substitute for natural blood pumping systems. With a team of skilled engineers, medical specialists, and business executives, BiVACOR has established a robust network for collaboration both in the United States and internationally, including an office in Brisbane, Australia.

BioCircuit Technologies, Inc. is a medical device company based in Atlanta, Georgia, founded in 2016. The company specializes in developing noninvasive electrophysiology devices that monitor, control, and repair peripheral nerves. By utilizing multi-electrode arrays and proprietary algorithms, BioCircuit's products enable clinicians to diagnose health conditions more effectively, track the progression of symptoms over time, and select tailored treatments for individual patients. This innovative approach enhances the ability of healthcare providers to address nerve-related health issues with greater precision and efficiency.